首页 正文

Signal transduction and targeted therapy. 2025 Feb 14;10(1):54. doi: 10.1038/s41392-025-02150-w Q140.82024

Full-length transcriptome atlas of gallbladder cancer reveals trastuzumab resistance conferred by ERBB2 alternative splicing

胆囊癌全长转录组图谱揭示了由ERBB2可变剪接引起的曲妥珠单抗耐药性 翻译改进

Ziyi Wang  1  2  3, Li Gao  4, Ziheng Jia  1  2  3, Liguo Liu  1  2  3, Ao Gu  1  2  3, Zhaonan Liu  1  2  3, Qin Zhu  3, Yichen Zuo  4, Mingjie Yang  1  2  3, Shijia Wang  5, Jiyao Ma  1  2  3, Jingyun Zhang  1  2  3, Shimei Qiu  1  2  3, Zhizhen Li  6, Jinghan Wang  7, Dongxi Xiang  2  3, Fatao Liu  2  3, Rong Shao  3  8  9, Yanjing Li  10  11, Maolan Li  12  13  14, Wu Wei  15, Yingbin Liu  16  17  18  19

作者单位 +展开

作者单位

  • 1 Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • 2 Shanghai Key Laboratory for Cancer Systems Regulation and Clinical Translation (CSRCT-SHANGHAI), Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • 3 State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital Affiliated to Shanghai Jiao Tong University school of Medicine, Shanghai, China.
  • 4 CAS Key Laboratory of Computational Biology, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China.
  • 5 Changzhou No.2 People Hospital Affiliated to Nanjing Medical University, Changzhou, China.
  • 6 Department of Biliary Tract Surgery I, Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
  • 7 Department of Hepatobiliary and Pancreatic Surgery, Institute of Hepatobiliary and Pancreatic Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
  • 8 Shanghai Key Laboratory of Biliary Tract Disease Research, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • 9 Department of Pharmacology and Biochemistry, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • 10 Shanghai Key Laboratory for Cancer Systems Regulation and Clinical Translation (CSRCT-SHANGHAI), Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. liyanjing@sjtu.edu.cn.
  • 11 State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital Affiliated to Shanghai Jiao Tong University school of Medicine, Shanghai, China. liyanjing@sjtu.edu.cn.
  • 12 Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. limaolan6@163.com.
  • 13 Shanghai Key Laboratory for Cancer Systems Regulation and Clinical Translation (CSRCT-SHANGHAI), Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. limaolan6@163.com.
  • 14 State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital Affiliated to Shanghai Jiao Tong University school of Medicine, Shanghai, China. limaolan6@163.com.
  • 15 Lingang Laboratory, Shanghai, China. wuwei@lglab.ac.cn.
  • 16 Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. laoniulyb@shsmu.edu.cn.
  • 17 Shanghai Key Laboratory for Cancer Systems Regulation and Clinical Translation (CSRCT-SHANGHAI), Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. laoniulyb@shsmu.edu.cn.
  • 18 State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital Affiliated to Shanghai Jiao Tong University school of Medicine, Shanghai, China. laoniulyb@shsmu.edu.cn.
  • 19 Department of General Surgery, Jiading Branch of Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. laoniulyb@shsmu.edu.cn.
  • DOI: 10.1038/s41392-025-02150-w PMID: 39948369

    摘要 Ai翻译

    Aberrant RNA alternative splicing in cancer generates varied novel isoforms and protein variants that facilitate cancer progression. Here, we employed the advanced long-read full-length transcriptome sequencing on gallbladder normal tissues, tumors, and cell lines to establish a comprehensive full-length gallbladder transcriptomic atlas. It is of note that receptor tyrosine kinases were one of the most dynamic components with highly variable transcript, with Erb-B2 receptor tyrosine kinase 2 (ERBB2) as a prime representative. A novel transcript, designated ERBB2 i14e, was identified for encoding a novel functional protein, and its protein expression was elevated in gallbladder cancer and strongly associated with worse prognosis. With the regulation of splicing factors ESRP1/2, ERBB2 i14e was alternatively spliced from intron 14 and the encoded i14e peptide was proved to facilitate the interaction with ERBB3 and downstream signaling activation of AKT. ERBB2 i14e was inducible and its expression attenuated anti-ERBB2 treatment efficacy in tumor xenografts. Further studies with patient derived xenografts models validated that ERBB2 i14e blockage with antisense oligonucleotide enhanced the tumor sensitivity to trastuzumab and its drug conjugates. Overall, this study provides a gallbladder specific long-read transcriptome profile and discovers a novel mechanism of trastuzumab resistance, thus ultimately devising strategies to improve trastuzumab therapy.

    Keywords:gallbladder cancer; transcriptome atlas; ERBB2 alternative splicing; trastuzumab resistance

    Copyright © Signal transduction and targeted therapy. 中文内容为AI机器翻译,仅供参考!

    相关内容

    期刊名:Signal transduction and targeted therapy

    缩写:

    ISSN:2095-9907

    e-ISSN:2059-3635

    IF/分区:40.8/Q1

    文章目录 更多期刊信息

    全文链接
    引文链接
    复制
    已复制!
    推荐内容
    Full-length transcriptome atlas of gallbladder cancer reveals trastuzumab resistance conferred by ERBB2 alternative splicing